Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Cash & Current Investments (2021 - 2026)

Indivior Pharmaceuticals has reported Cash & Current Investments over the past 6 years, most recently at $175.0 million for Q1 2026.

  • For Q1 2026, Cash & Current Investments fell 53.08% year-over-year to $175.0 million; the TTM value through Mar 2026 reached $175.0 million, down 53.08%, while the annual FY2025 figure was $195.0 million, 35.43% down from the prior year.
  • Cash & Current Investments for Q1 2026 was $175.0 million at Indivior Pharmaceuticals, down from $195.0 million in the prior quarter.
  • Over five years, Cash & Current Investments peaked at $931.0 million in Q2 2022 and troughed at $175.0 million in Q1 2026.
  • A 5-year average of $524.0 million and a median of $477.5 million in 2025 define the central range for Cash & Current Investments.
  • Biggest five-year swings in Cash & Current Investments: tumbled 57.89% in 2024 and later soared 74.06% in 2025.
  • Year by year, Cash & Current Investments stood at $893.0 million in 2022, then dropped by 18.14% to $731.0 million in 2023, then plummeted by 56.22% to $320.0 million in 2024, then tumbled by 39.06% to $195.0 million in 2025, then fell by 10.26% to $175.0 million in 2026.
  • Business Quant data shows Cash & Current Investments for INDV at $175.0 million in Q1 2026, $195.0 million in Q4 2025, and $445.0 million in Q3 2025.